Cargando…

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis

This is a phase Ib/II study of regorafenib plus toripalimab for colorectal cancer. The objective response rate (ORR) is 15.2% and the disease control rate is 36.4% in evaluable patients with recommended phase II dose (80 mg regorafenib plus toripalimab). The median progression-free survival (PFS) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Feng, He, Ming-Ming, Yao, Yi-Chen, Zhao, Xia, Wang, Zhi-Qiang, Jin, Ying, Luo, Hui-Yan, Li, Ji-Bin, Wang, Feng-Hua, Qiu, Miao-Zhen, Lv, Zhi-Da, Wang, De-Shen, Li, Yu-Hong, Zhang, Dong-Sheng, Xu, Rui-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484502/ https://www.ncbi.nlm.nih.gov/pubmed/34622226 http://dx.doi.org/10.1016/j.xcrm.2021.100383

Ejemplares similares

Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer
por: Yu, Wei, et al.
Publicado: (2021)

Regorafenib alone or in combination with high/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT)
por: Zhou, Shujuan, et al.
Publicado: (2023)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
por: Wei, Xiao‐Li, et al.
Publicado: (2020)

Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study
por: Zhou, Yu-Wen, et al.
Publicado: (2022)

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
por: Cao, Yanshuo, et al.
Publicado: (2022)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
por: Wang, Yunchao, et al.
Publicado: (2023)

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis
por: Bai, Long, et al.
Publicado: (2016)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial
por: Chen, Si-Yuan, et al.
Publicado: (2023)

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
por: Clarke, Jeffrey Melson, et al.
Publicado: (2019)

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
por: Zhou, Hong, et al.
Publicado: (2021)

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
por: Patel, Anuj K., et al.
Publicado: (2019)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial
por: Xu, Jianming, et al.
Publicado: (2020)

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer
por: Ma, Cheng-Jen, et al.
Publicado: (2017)

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G(4) Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
por: Sheng, Xinan, et al.
Publicado: (2019)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
por: Lin, Jingrong, et al.
Publicado: (2020)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Phase II clinical trial of S‐1 plus nanoparticle albumin‐bound paclitaxel in untreated patients with metastatic gastric cancer
por: He, Ming‐ming, et al.
Publicado: (2018)

Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer
por: Chen, Beibei, et al.
Publicado: (2022)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
por: Su, Guan-Li, et al.
Publicado: (2020)

Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer
por: Haque, Emaan, et al.
Publicado: (2022)

Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: A case report
por: Liu, Rui, et al.
Publicado: (2022)

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer
por: Fogelman, David, et al.
Publicado: (2018)

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
por: Wang, Feng-Hua, et al.
Publicado: (2021)

Is neutrophil-to-lymphocyte ratio and C-reactive protein the prognostic role in metastatic colorectal cancer using regorafenib?
por: Chen, Xinyang, et al.
Publicado: (2023)

The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study
por: Li, Jisheng, et al.
Publicado: (2020)

Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study
por: Li, Rong-Rong, et al.
Publicado: (2022)

A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients
por: Yang, Lu-Ping, et al.
Publicado: (2019)

S‐1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial
por: Chen, Ye, et al.
Publicado: (2019)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study
por: Lin, Chun-Yu, et al.
Publicado: (2018)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer
por: Lim, Yoojoo, et al.
Publicado: (2015)

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_38ea2500274l8k379nk8us15u1